Migraine: A Review on Its History, Symptoms, And Its Treatment

Amulya Polimetla; Sahithi Varma Kakarlapudi; Bias Rekha Singh Tilakchand; Suneetha A; Jahnavi Patibandla

doi:10.37022/jpmhs.v8i2.133

Authors

Polimetla Amulya KVSR Siddartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India.
Kakarlapudi Sahithi Varma KVSR Siddartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India.
Tilakchand Bias Rekha Singh KVSR Siddartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India.
A. Suneetha KVSR Siddartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India.
Patibandla Jahnavi KVSR Siddartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India.

DOI:

https://doi.org/10.37022/jpmhs.v8i2.133

Abstract

Migraine is a prevalent and disabling neurological disorder characterized by recurrent episodes of moderate to severe headache, often accompanied by nausea, vomiting, photophobia, and phonophobia. Historically documented in Egyptian, Greek, and Roman medical texts, the understanding of migraine has evolved from humoral theories to modern neurovascular models. Migraine is classified into several subtypes, with migraine without aura being the most common. Clinical presentation often follows a multi-phase pattern including prodrome, aura, headache, and postdrome. The pathophysiology involves cortical spreading depression, activation of the trigeminovascular system, release of inflammatory neuropeptides like CGRP, serotonin dysregulation, and genetic predisposition. Diagnosis is guided by the ICHD-3 criteria and requires differentiation from other headache types such as tension-type and cluster headaches. Treatment includes both acute therapies (e.g., triptans, NSAIDs, gepants) and preventive approaches (e.g., beta-blockers, CGRP monoclonal antibodies). Non-pharmacological interventions such as cognitive behavioral therapy, neuromodulation devices, and dietary supplements offer additional benefits. Recent advances include CGRP-targeted drugs, wearable technologies, and personalized medicine strategies. This review emphasizes the need for early diagnosis, individualized treatment, and multidisciplinary care to improve outcomes. Continued research on biomarkers and new therapeutic targets holds promise for better prevention and management of migraine.

Downloads

Download data is not yet available.

References

Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.

Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: A disorder of sensory processing. Physiol Rev. 2017;97(2):553–622.

Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174–82.

Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015;55(1):21–34.

Lipton RB, Bigal ME. The epidemiology of migraine. Am J Med. 2005;118(1):3–10.

Kelman L. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache. 2004;44(9):865–72.

Ferrari MD. Migraine. Lancet. 1998;351(9108):1043–51.

Lauritzen M. Pathophysiology of the migraine aura: The spreading depression theory. Brain. 1994;117(Pt 1):199–210.

Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013;75:365–91.

Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(Suppl 2):47–55.

Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010;9(3):285–98.

Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60(6):1259–87.

Dodick DW. Migraine. Lancet. 2018;391(10127):1315–30.

Tepper SJ. CGRP and migraine: the role of monoclonal antibodies. Headache. 2018;58(Suppl 1):33–47.

Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55(Suppl 2):103–22.

Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015;21(4):973–89.

Diener HC, Charles A, Goadsby PJ, Holle D. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol. 2015;14(10):1010–22.

Messina R, Goadsby PJ. CGRP monoclonal antibodies for migraine prevention. Curr Opin Neurol. 2021;34(3):376–85.

Buse DC, Greisman JD, Baigi K, Lipton RB. Migraine progression: a systematic review. Headache. 2019;59(3):306–38.

May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12(8):455–64.

Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021;397(10283):1505–18.

Goadsby PJ. Neuromodulation in primary headaches. Cephalalgia. 2014;34(5):355–61.

Silberstein SD, Dodick DW, Pearlman SH. Headache. Med Clin North Am. 2009;93(2):215–31.

Lanteri-Minet M. Economic burden and costs of chronic migraine. Curr Pain Headache Rep. 2014;18(1):385.

Goadsby PJ. CGRP antagonists for acute migraine treatment. Lancet. 2019;394(10203):533–5.

Akerman S, Romero-Reyes M, Holland PR. Targeting CGRP for the treatment of migraine: pharmacological mechanisms and clinical implications. CNS Drugs. 2020;34(9):805–20.

Starling AJ. Personalized medicine for migraine: a future paradigm. Headache. 2018;58(Suppl 1):45–56.

Raffaelli B, Neeb L, Reuter U. Monoclonal antibodies for the prevention of migraine. Expert OpinBiol Ther. 2019;19(12):1307–17.

Brennan KC, Charles A. An update on the blood–brain barrier in migraine. Headache. 2010;50(6):1040–56.

Charles A. The evolution of a migraine attack—a review of recent evidence. Headache. 2013;53(2):413–9.

Alstadhaug KB. Migraine and the hypothalamus. Cephalalgia. 2009;29(8):809–17.

Olesen J. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther. 2008;120(2):157–71.

Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J, et al. The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache. 2012;52(4):582–91.

Pringsheim T, Davenport W, Mackie G, Christie SN, Aubé M, Gladstone J, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39(2 Suppl 2):S1–59.

Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment. Headache. 2015;55(1):3–20.

Kelman L. Pain characteristics of migraine with and without aura. Headache. 2004;44(9):856–60.

Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33(1):48–56.

Holland PR, Headache: pathophysiology and clinical targets for treatment. Expert Opin Ther Targets. 2014;18(8):943–53.

Russell MB, Olesen J. The genetics of migraine without aura and migraine with aura. Cephalalgia. 1993;13(4):245–8.

Sances G, Guaschino E, Ghiotto N, Allena M, Tassorelli C. Medication overuse headache: epidemiology and management. Neurol Sci. 2019;40(Suppl 1):107–13.

Ashina M, Hansen JM, Á Dunga BO, Olesen J. Migraine and the trigeminovascular system—40 years and counting. Lancet Neurol. 2019;18(8):795–804.

Ford JH, Jackson J, Milligan G, Cotton S, Ahl J, Aurora SK. A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache. 2017;57(10):1532–44.